Amprenavir

Drug #1731

Amprenavir is an antiviral agent, active against HIV infection. It belongs to protease inhibitors. Amprenavir is used in combination with other antiretroviral drugs in the treatement of HIV infection and AIDS.

← Previous drug Next drug →

Primary Characteristics

It is of Synthetic origin.

Molecular Weight: 505.63 · Solubility in Water: 4.91e-02mg/mL · Non-proprietary name: Amprenavir.

Pharmacokinetics

Distribution: Amprenavir has a plasma protein binding is 90%.

Elimination: plasma half-life is 7.1-10.6hrs.

Indications

Amprenavir is primarily indicated in conditions like Gastric acid reduction during anaesthesia, HIV infection in combination with other antiretroviral drugs.

Contraindications

Amprenavir is contraindicated in conditions like Pregnancy, Liver damage, Kidney disease, Breast feeding.

Dosage

Amprenavir's dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
1200 mg twice a day	1200 mg twice a day	—	Oral	For liquid filled capsules
1400 mg twice a day	1400 mg twice a day	—	Oral	For oral solutions
Paediatric Dosage (20kg)
No data.
Neonatal Dosage (3kg)
No data.

Drug Interactions

11 interactions

Major17 interactions

Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Side Effects

Amprenavir is known to cause more or less tolerable side effects which are usually transient. These include Abdominal pain, Blood disorders including anemia, and neutropenia, Depression, Diarrhea, Dizziness, Fatigue, Flatulence, GI disturbance, Headache, Hypersensitivity reactions, Hypotension , Nausea and vomiting, Pruritus , Rashes .

Warnings / Precautions

Amprenavir should be used with caution in patients with hepatic impairment (May need dose reduction); pregnancy (use only if potential benefit outweighs risk); diabetes; haemophilia; avoid vitaminE suppliments (vit.E included in formulation); oral solution contains propylene glycol----avoid in hepatic impairment, in severe renal impairment, in pregnancy, and avoid concomitant metronidazole, disulfiram, or preparation containing alcohol or propylene glycol; increased susceptibility to propylene glycol toxicity in slow metaboliser.RASH: Rash may occur, usually in the second week of therapy; discontinue permanently if severe rash with systemic or allergic symptoms or, mucosal involvement; if rash mild or moderate, may continue without interruption----rash usally resolves within two weeks and may respond to antihistamines.

Available Brands

None recorded.

Storage Conditions

Amprenavir should be stored caps, Solutions.

Drug Classification

1.6.5.2 — Antiretroviral drugs